LYRA — Lyra Therapeutics Balance Sheet
0.000.00%
- $3.23m
- -$18.82m
- $1.53m
Annual balance sheet for Lyra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 74.6 | 45.7 | 97.9 | 103 | 40.6 |
| Prepaid Expenses | |||||
| Total Current Assets | 75.9 | 47.9 | 101 | 105 | 43 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.47 | 5.86 | 4.47 | 35.3 | 21.3 |
| Other Long Term Assets | |||||
| Total Assets | 80.8 | 54.9 | 110 | 143 | 66.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.88 | 18.2 | 14.5 | 19.6 | 12.6 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.34 | 20.6 | 29.2 | 53.2 | 54.8 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 74.5 | 34.3 | 80.8 | 89.4 | 11.6 |
| Total Liabilities & Shareholders' Equity | 80.8 | 54.9 | 110 | 143 | 66.3 |
| Total Common Shares Outstanding |